

Supplementary Table 2. Risk factors for death in BCLC 0 stage patients with HCC (n=173)

Variable	Univariate			Multivariate		
	HR	95% CI	P-value	HR	95% CI	P-value
Etiology						
HBV	Ref					
HCV	2.200	0.825-5.866	0.115			
NBNC	2.447	1.112-5.382	0.026	2.000	0.893-4.481	0.092
Age (years)	1.025	0.988-1.063	0.192			
Male sex	0.936	0.447-1.962	0.862			
Hypertension	1.175	0.509-2.709	0.706			
Diabetes	2.052	0.999-4.213	0.050			
Smoking	1.160	0.586-2.298	0.670			
Alcohol	1.191	0.601-2.358	0.617			
Albumin (g/dL)	0.430	0.249-0.741	0.002	0.467	0.264-0.828	0.009
Total bilirubin (mg/dL)	1.267	0.743-2.162	0.384			
Prothrombin time (INR)	8.743	0.475-160.972	0.145			
AST (U/L)	1.002	0.999-1.006	0.194			
ALT (U/L)	1.002	0.997-1.006	0.465			
Tumor size (cm)	0.963	0.868-1.067	0.470			
AFP (ng/mL)	1.000	0.998-1.001	0.898			
PIVKA-II (mAU/mL)	1.000	0.999-1.001	0.765			

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-B non-C; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by the absence of vitamin K or antagonist-II; 95% CI, 95% confidence interval; HR, hazard ratio; Ref, reference.